NSRX (Nasus Pharma) Preferred Stock: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSRX Nasus Pharma Ltd NSRX
14 GF Score
Price $3.00
! 4 Warning Signs
View Full Analysis

What is Nasus Pharma Preferred Stock?

Nasus Pharma NSRX -3.01% 14 Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Nasus Pharma's preferred stock for the quarter that ended in Dec. 2025 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Nasus Pharma's Enterprise Value for the quarter that ended in Dec. 2025 was $78.27 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Nasus Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was $0.31.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Nasus Pharma's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $-0.51.


Nasus Pharma  (AMEX:NSRX) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Nasus Pharma's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Nasus Pharma's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Nasus Pharma's Earnings per Share (Diluted) (EPS) for the six months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nasus Pharma Preferred Stock Related Terms


Nasus Pharma Preferred Stock Historical Data

* Premium members only.

The historical data trend for Nasus Pharma's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nasus Pharma Preferred Stock Chart

Nasus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Preferred Stock
0.00 0.00 0.00 0.00

Nasus Pharma Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Preferred Stock Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSRX
14GF Score
Nasus Pharma Ltd NSRX
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nasus Pharma Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of $0.00 Mil mean?
Nasus Pharma (NSRX) has a Preferred Stock of $0.00 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on Nasus Pharma and its competitors.
Is Nasus Pharma's Preferred Stock too high?
Nasus Pharma's current Preferred Stock is $0.00 Mil. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's Preferred Stock compare to MIRA and SCLX?
Nasus Pharma's Preferred Stock of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Drug Manufacturers company?
A good Preferred Stock depends on the Drug Manufacturers industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Nasus Pharma and its competitors. Nasus Pharma's current Preferred Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current Preferred Stock of $0.00 Mil. The current Preferred Stock is $0.00 Mil. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nasus Pharma Business Description

Address Yigal Alon 65, Tel Aviv, ISR, 6744317
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score

Get the complete analysis for NSRX

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price